

AUTHOR CORRECTION

Author Correction: Clinical Benefit of Basal Insulin Analogue Treatment in Persons with Type 2 Diabetes Inadequately Controlled on Prior Insulin Therapy: A Prospective, Noninterventional, Multicenter Study

Jelica Bjekić-Macut · Teodora Beljić Živković  · Radivoj Kocić

Published online: March 22, 2018
© The Author(s) 2018

Author Correction to: Diabetes Ther
<https://doi.org/10.1007/s13300-018-0378-4>

in the Swedish study (0.33 ± 0.16 U/kg body weight/day)".

In the original publication, values of the doses of insulin glargine, the most commonly used basal insulin analogue under the 'Discussion' section was incorrectly published.

The sentence "...was similar (3100.314 ± 110.1298 U/kg body weight/day at baseline) to that in the Swedish study (0.33 ± 0.16 U/kg body weight/day)".

Should actually say "...was similar (0.31 ± 0.12 U/kg body weight/day at baseline) to that

Open Access. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits any non-commercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

The original article can be found online at <https://doi.org/10.1007/s13300-018-0378-4>.

J. Bjekić-Macut
Belgrade School of Medicine, Bezanijska Kosa
University Medical Center, Division of
Endocrinology, Diabetes and Metabolic disorders,
University of Belgrade, Belgrade, Serbia

T. B. Živković (✉)
Belgrade School of Medicine, "Zvezdara" University
Medical Center, Division of Endocrinology,
Diabetes and Metabolic disorders, University of
Belgrade, Belgrade, Serbia
e-mail: dorabeljic@beotel.net

R. Kocić
Clinic for Endocrinology, Faculty of Medicine,
University of Nis, Nis, Serbia